Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUL cardiovascular outcomes trial of oral semaglutide in type 2 diabetes
MOH_2019-05-30_007151Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide with Placebo (2 arms). Primary endpoint: Major adverse cardiovascular events. Started May 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2019-05-30_007151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-30_007151.